【全球抗疫】巴西专家：中国疫苗全球领先！_风闻

前段时间，关于中国的新冠疫苗出现了平行时空：

西方主流媒体疯狂抹黑中国疫苗，同时，很多国家大量购买中国的疫苗，而且很多外国政要也纷纷带头接种中国疫苗。

这个世界上，没有人是傻子。西方媒体的操作无非是意识形态+利益驱动。而菲律宾总统杜特尔特的评论则是一针见血！

中国疫苗在海外的试验，包括土耳其和印尼的试验结果也有不少差距。偏偏中国疫苗的生产商深知西方媒体的“德性”，所以懒得向西方媒体解释。（试验结果的影响因素有很多，不在此解释，有兴趣的网友可自行了解）

但是，我相信一定有很多网友和我一样对中国疫苗之谜既不甘（被抹黑）又好奇！经过多番寻找，我终于找到了，下面就为大家解谜！

让我们把目光聚焦巴西---全球战疫的主要战场之一，也是所有疫苗的主要和必要试验地！

这篇美媒《财富杂志》的报道虽然不怎么样，但是其中对巴西专家的采访才是我们关注的重点！

科兴疫苗Sinovac的巴西合作伙伴是Butantan Institute。

Butantan研究所的医学主任RicardoPalácios认为，较低的功效率证明了Sinovac科兴疫苗在巴西的试验比Pfizer和Moderna试验更关注高风险人群，并且该研究所使用了更严格的标准。他说：“我们（在我们的试验中）增加了所有可能的困难。”

帕拉西奥斯（Palácios）表示，科兴疫苗（Sinovac）的相对较低的50％的效率是由于其对被视为试验志愿者的感染的标准更为严格。 Butantan研究所表示，其结果包括六种类型的病例：无症状，非常轻度，轻度，中度和重度两个级别。 （巴西当局强调，公众应关注该疫苗在预防COVID-19严重病例方面的100％功效。）西方疫苗生产商通常只包括轻度，中度和重度类别，辉瑞公司等公司正在开展更多研究看看疫苗是否可以预防无症状病例。

帕拉西奥斯说：“人们想比较其他研究，但这就像比较一个人在平坦的伸展运动中跑一公里的比赛和另一个在陡峭且充满障碍的伸展运动中跑的人。”

有一些证据支持Palácios的说法，即巴西的试验标准比其他地方进行的试验更可能捕获轻度COVID-19病例，这将导致较低的有效率。

在美国食品药品监督管理局（FDA）对辉瑞疫苗试验的评估中，该机构发现多达1,594例疑似但未经证实的COVID-19病例。由于尚未确定感染情况，因此没有将其纳入辉瑞疫苗的功效率。

Sinovac’s Brazilian partner, the Butantan Institute.

Ricardo Palácios, medical director of the Butantan Institute, argued that the lower efficacy rate was evidence that Sinovac’s Brazil trials focused on higher risk groups than the Pfizer and Moderna trials and that the institute used more stringent standards. “We added all possible difficulties [to our trials],” he said. 

Palácios said Sinovac’s relatively low efficacy rate of 50% was due to its more rigorous standard for what counts as an infection among trial volunteers. The Butantan Institute said it included six types of cases in its results: asymptomatic, very mild, mild, two levels of moderate, and severe. (The Brazilian authorities stressed that the public should focus on the vaccine’s 100% efficacy in protecting against severe cases of COVID-19.) Western vaccine makers generally included only mild, moderate, and severe categories, and companies like Pfizer are doing additional studies to see if the vaccine will prevent asymptomatic cases.

“People want to compare other studies, but that’s like comparing a person that runs a 1-kilometer race on a flat stretch and another doing it on a steep and obstacle-filled stretch,” Palácios said.

There is some evidence to back up Palácios’ claim that Brazil’s trial standards are more likely to catch mild cases of COVID-19 than trials conducted elsewhere, which would result in a lower efficacy rate.

In the U.S.’s Food and Drug Administration’s evaluation of Pfizer’s vaccine trials, the agency found that there were up to 1,594 suspected but unconfirmed cases of COVID-19. Because the infections were unconfirmed, they didn’t factor into the Pfizer vaccine’s efficacy rate.